"I'm wondering if he thinks the same thing about J&J's decision to spend $200M on a vaccine that may not work and may not be ready in time for the current outbreak?"
I believe his response is a reasonable one. Given that I'm knee deep in JNJ I can only hope that their experience...something that is lacking here (relatively speaking)...mitigates against the rather substantial risk.